Nothing Special   »   [go: up one dir, main page]

CO2020004249A2 - Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso - Google Patents

Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso

Info

Publication number
CO2020004249A2
CO2020004249A2 CONC2020/0004249A CO2020004249A CO2020004249A2 CO 2020004249 A2 CO2020004249 A2 CO 2020004249A2 CO 2020004249 A CO2020004249 A CO 2020004249A CO 2020004249 A2 CO2020004249 A2 CO 2020004249A2
Authority
CO
Colombia
Prior art keywords
methods
cystic fibrosis
fibrosis transmembrane
conductance regulator
transmembrane conductance
Prior art date
Application number
CONC2020/0004249A
Other languages
English (en)
Inventor
Gregory A Gfesser
Nicolas Desroy
Christopher Gaëtan Housseman
Philip R Kym
Mathieu Rafaël Pizzonero
Der Plas Steven Emiel Van
Robert J Altenbach
Andrew Bogdan
Sylvain Couty
Bo Liu
Thi Thu Trang Mai
Karine Fabienne Malagu
Merayo Nuria Merayo
Olivier Laurent Picolet
Xenia B Searle
Xueqing Wang
Ming C Yeung
Original Assignee
Galapagos Nv
Abbvie Overseas Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv, Abbvie Overseas Sarl filed Critical Galapagos Nv
Publication of CO2020004249A2 publication Critical patent/CO2020004249A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Sanitary Thin Papers (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)

Abstract

La invención divulga compuestos de la Fórmula (I), I, en donde A1, R1, R2, R3, R4 y n son como se definen en la presente. La presente invención se refiere a compuestos y su uso en el tratamiento de la fibrosis quística, métodos para su producción, composiciones farmacéuticas que los comprenden y métodos para tratar la fibrosis quística mediante la administración de un compuesto de la invención.
CONC2020/0004249A 2017-09-14 2020-04-07 Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso CO2020004249A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558430P 2017-09-14 2017-09-14
US201762608846P 2017-12-21 2017-12-21
PCT/IB2018/057020 WO2019053634A1 (en) 2017-09-14 2018-09-13 MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATORY PROTEIN OF CYSTIC FIBROSIS AND METHODS OF USE

Publications (1)

Publication Number Publication Date
CO2020004249A2 true CO2020004249A2 (es) 2020-08-31

Family

ID=63713961

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0004249A CO2020004249A2 (es) 2017-09-14 2020-04-07 Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso

Country Status (33)

Country Link
US (6) US10988454B2 (es)
EP (4) EP3736267B1 (es)
JP (4) JP7064072B2 (es)
KR (1) KR20200086661A (es)
CN (1) CN111954664A (es)
AU (1) AU2018332512A1 (es)
BR (1) BR112020005102A2 (es)
CA (1) CA3074945A1 (es)
CL (1) CL2020000664A1 (es)
CO (1) CO2020004249A2 (es)
CR (1) CR20200157A (es)
CY (3) CY1123761T1 (es)
DK (3) DK3736267T3 (es)
EC (1) ECSP20021913A (es)
ES (3) ES2881881T3 (es)
HR (3) HRP20210099T1 (es)
HU (3) HUE055050T2 (es)
IL (1) IL273163A (es)
LT (3) LT3736267T (es)
MA (1) MA50240B1 (es)
MD (3) MD3681864T2 (es)
MX (1) MX2020002806A (es)
PE (1) PE20210140A1 (es)
PH (1) PH12020500509A1 (es)
PL (3) PL3681864T4 (es)
PT (3) PT3736267T (es)
RS (3) RS62190B1 (es)
RU (1) RU2020113350A (es)
SG (1) SG11202002101RA (es)
SI (3) SI3681864T1 (es)
UA (1) UA125541C2 (es)
WO (1) WO2019053634A1 (es)
ZA (1) ZA202002363B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ768368A (en) 2014-10-06 2024-03-22 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
HRP20211683T1 (hr) 2016-09-30 2022-03-04 Vertex Pharmaceuticals Incorporated Modulator transmembranskog regulatora provodljivosti cistične fibroze, farmaceutski pripravci, postupci liječenja, i postupak za pripravu modulatora
US10793547B2 (en) 2016-12-09 2020-10-06 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
NZ761388A (en) 2017-07-17 2024-07-26 Vertex Pharma Methods of treatment for cystic fibrosis
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
HUE056615T2 (hu) 2017-10-18 2022-02-28 Incyte Corp Tercier hidroxicsoportokkal szubsztituált kondenzált imidazol-származékok mint PI3K-gamma inhibitorok
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
IL276662B (en) 2018-02-15 2022-08-01 Vertex Pharma Macrocycles as modulators of the cystic fibrosis transmembrane conductance regulator, their pharmaceutical compounds, their use in the treatment of cystic fibrosis, and a process for their preparation.
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP3897832B1 (en) * 2018-12-18 2023-10-11 Novartis AG N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide derivatives and their use in the treatment of a cftr mediated disease
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US11873300B2 (en) 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
US20220211692A1 (en) * 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
US20220213041A1 (en) * 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB602426A (en) * 1945-10-24 1948-05-26 Geigy Ag J R Manufacture of aromatic acyl-sulphonamides
MXPA03003174A (es) * 2000-10-10 2003-07-14 Smithkline Beecham Corp Indoles substituidos, composiciones farmaceuticas que contienen dichos indoles y su uso como agentes de enlace ppar-y..
CA2569402A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
BR122018075478B8 (pt) 2004-06-24 2023-10-31 Vertex Pharma moduladores de transportadores de cassete de ligação de atp
ES2646175T3 (es) 2006-11-03 2017-12-12 Vertex Pharmaceuticals Incorporated Derivados de azaindol como moduladores de CFTR
EP2170901B1 (en) 2007-05-25 2015-07-01 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AR068107A1 (es) * 2007-08-29 2009-11-04 Schering Corp Derivados indolicos 2,3 sustituidos y una composicion farmaceutica
JP5249344B2 (ja) * 2007-11-16 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション ヘテロ環の３位が置換されたインドール誘導体およびその使用
KR101578235B1 (ko) 2007-12-10 2015-12-16 노파르티스 아게 유기 화합물
CN101925603B (zh) 2007-12-13 2013-12-04 沃泰克斯药物股份有限公司 囊性纤维化跨膜通道调节因子的调节剂
BRPI0908706A2 (pt) 2008-03-25 2015-07-28 Univ California Inibidores de mólecula pequena solúvel em água do regulador de condutância de transmembrana de fibrose cística
PL2358680T3 (pl) 2008-10-23 2013-08-30 Vertex Pharma Stałe postacie N-(4-(7-azabicyklo[2.2.1]heptan-7-ylo)-2-(trifluorometylo)fenylo)-4-okso-5-(trifluorometylo)-1,4-dihydrochinolino-3-karboksyamidu
PL2365972T3 (pl) 2008-11-06 2015-05-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
WO2010078103A1 (en) 2008-12-30 2010-07-08 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20120129858A1 (en) * 2009-04-20 2012-05-24 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine sulfonamide derivatives
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
BR112013007907A2 (pt) 2010-10-08 2016-06-14 N30 Pharmaceuticals Inc novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
CN103946221B (zh) 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2716723T3 (es) 2011-09-20 2019-06-14 Univ North Carolina Chapel Hill Regulación de los canales de sodio por las proteínas PLUNC
CA2911453C (en) 2013-05-07 2021-08-03 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
AU2014304562B8 (en) 2013-08-08 2018-07-05 Galapagos Nv Thieno[2,3-c]pyrans as CFTR modulators
CN103484818A (zh) 2013-09-25 2014-01-01 京东方科技集团股份有限公司 蒸镀方法、蒸镀装置和发光器件
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015138934A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
KR102132215B1 (ko) 2014-04-03 2020-07-09 삼성전자주식회사 자기 터널 접합 구조물 형성 방법 및 이를 이용한 자기 메모리 소자의 제조 방법
NZ768368A (en) 2014-10-06 2024-03-22 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
SG11201703391VA (en) 2014-10-31 2017-05-30 Abbvie S À R L Substituted chromanes and method of use
AU2015339196A1 (en) 2014-10-31 2017-05-11 Abbvie S.A.R.L. Substituted tetrahydropyrans and method of use
CN107922338A (zh) 2015-06-02 2018-04-17 艾伯维公司 经取代的吡啶及使用方法
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
KR20180083323A (ko) 2015-10-09 2018-07-20 애브비 에스.에이.알.엘. N-설포닐화 피라졸로[3,4-b]피리딘-6-카복스아미드 및 사용 방법
CA3016303A1 (en) 2016-04-26 2017-11-02 Abbvie S.A.R.L. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use

Also Published As

Publication number Publication date
RS61899B1 (sr) 2021-06-30
RU2020113350A (ru) 2021-10-15
MD3681864T2 (ro) 2021-05-31
LT3681864T (lt) 2021-02-25
CN111954664A (zh) 2020-11-17
PT3736270T (pt) 2021-08-10
ZA202002363B (en) 2021-06-30
EP3736270A1 (en) 2020-11-11
PL3736267T3 (pl) 2021-11-15
EP3681864B1 (en) 2020-10-28
US10981890B2 (en) 2021-04-20
US20200277275A1 (en) 2020-09-03
CY1123761T1 (el) 2022-05-27
LT3736270T (lt) 2021-08-25
SI3736270T1 (sl) 2021-09-30
PL3681864T3 (pl) 2021-05-17
RS62190B1 (sr) 2021-08-31
KR20200086661A (ko) 2020-07-17
HRP20211200T1 (hr) 2021-10-29
IL273163A (en) 2020-04-30
HUE055241T2 (hu) 2021-11-29
SI3681864T1 (sl) 2021-08-31
HUE052873T2 (hu) 2021-05-28
CY1124401T1 (el) 2022-07-22
LT3736267T (lt) 2021-08-25
DK3681864T3 (da) 2021-01-25
AU2018332512A1 (en) 2020-04-23
JP7064073B2 (ja) 2022-05-10
MD3736267T2 (ro) 2021-11-30
US20200277274A1 (en) 2020-09-03
US10829473B2 (en) 2020-11-10
PL3681864T4 (pl) 2021-05-17
JP2022000461A (ja) 2022-01-04
JP2020534360A (ja) 2020-11-26
ES2887449T3 (es) 2021-12-22
EP3736267B1 (en) 2021-05-05
MX2020002806A (es) 2020-10-12
RU2020113350A3 (es) 2022-04-14
SG11202002101RA (en) 2020-04-29
JP7064072B2 (ja) 2022-05-10
EP3865474A1 (en) 2021-08-18
RS62185B1 (sr) 2021-08-31
US20210238159A1 (en) 2021-08-05
US20200277273A1 (en) 2020-09-03
CY1124615T1 (el) 2022-07-22
ES2881881T3 (es) 2021-11-30
CR20200157A (es) 2021-02-16
PH12020500509A1 (en) 2021-05-31
SI3736267T1 (sl) 2021-09-30
US10844041B2 (en) 2020-11-24
ECSP20021913A (es) 2020-05-29
US20190077784A1 (en) 2019-03-14
EP3736270B1 (en) 2021-05-05
EP3736267A1 (en) 2020-11-11
PL3736270T3 (pl) 2021-11-15
BR112020005102A2 (pt) 2020-09-24
EP3681864A1 (en) 2020-07-22
JP7064074B2 (ja) 2022-05-10
CA3074945A1 (en) 2019-03-21
MA50240A (fr) 2020-07-22
CL2020000664A1 (es) 2020-11-06
HUE055050T2 (hu) 2021-10-28
US20200277276A1 (en) 2020-09-03
US10988454B2 (en) 2021-04-27
PE20210140A1 (es) 2021-01-21
JP2022000460A (ja) 2022-01-04
US10844042B2 (en) 2020-11-24
PT3681864T (pt) 2021-02-25
MD3736270T2 (ro) 2021-11-30
ES2856751T3 (es) 2021-09-28
PT3736267T (pt) 2021-08-10
WO2019053634A1 (en) 2019-03-21
HRP20211198T1 (hr) 2021-10-29
DK3736270T3 (da) 2021-08-09
JP2022062093A (ja) 2022-04-19
HRP20210099T1 (hr) 2021-03-05
MA50240B1 (fr) 2021-03-31
DK3736267T3 (da) 2021-08-09
UA125541C2 (uk) 2022-04-13

Similar Documents

Publication Publication Date Title
CO2020004249A2 (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
DOP2016000041A (es) Compuestos derivados de 5,5,7,7-tetrametil-5,7-dihidro-4h-tieno[2,3-c]piran-3-carboxamida que son moduladores del regulador de la conductancia transmembrana de la fibrosis quística (cftr)
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
DOP2017000278A (es) Piridinas sustituidas y método de uso
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
NI201800076A (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2018002920A1 (es) Nuevos derivados de pirazolopirimidina
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
NI201800132A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
BR112015027964A2 (pt) Compostos moduladores do regulador de condutância transmembrana da fibrose cística (cftr), composições farmacêuticas compreendendo os mesmos e uso destes para o tratamento da fibrose cística
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
UY36735A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201500050A (es) Benzamidas
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
UY37973A (es) Derivados de indol macrocíclicos
UY37348A (es) Agentes antibacterianos de 2-pirrolidin fenilhidrazidas
CO2022002022A2 (es) Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias
UY37032A (es) Compuestos de heteroarilbenzimidazol